Revolutionizing Endoscopic Treatment

From Fritz Haller, CEO, Endolastic

Endolastic Q2 2025 Investor Update

Credibility Proven. Scalability Unlocked

Investment Snapshot

Endolastic is raising a $4M physician-led seed round:

• $515,000 already committed
• SAFE at $20M post-money valuation
• Minimum investment: $25,000

Funds support commercial launch, regulatory filings, and expansion into diabetes. We now have clinical data, KOL backing, and a differentiated platform built for real-world impact.

New Advisory Board Addition: Dr. Todd H. Baron

We’re honored to welcome Dr. Todd Baron, Director of Advanced Therapeutic Endoscopy at UNC Chapel Hill, to our Scientific Advisory Board. Dr. Baron is one of the world’s most accomplished interventional endoscopists with over 600 peer-reviewed publications, lead editor of the definitive ERCP textbook, and recipient of the 2023 Rudolf V. Schindler Award—the highest honor in GI endoscopy. His clinical focus spans the entire GI tract, making him an ideal partner to help guide Endolastic across GERD, obesity, and diabetes.

Clinical Progress

• 50+ successful human cases completed with Gen 1 EndoBand™
• 85%+ GERD symptom resolution via Anti-Reflux Band Mucosectomy (ARBM)
  By comparison, the leading alternative—TIF (Transoral Incisionless Fundoplication)—shows GERD symptom resolution in the 68–75% range across most published series.¹
• 20%+ weight loss in Endoscopic Band Gastroplasty (EBG) cases
  For reference, Boston Scientific’s OverStitch-based ESG (Endoscopic Sleeve Gastroplasty) reports weight loss in the 15–18% range at 12 months.²
• Zero serious adverse events (SAEs) reported
  By contrast, TIF for GERD and ESG for obesity—two leading endoscopic procedures—report SAE rates of 2.3–2.4%.³⁻⁴

EndoBand™ has demonstrated zero SAEs across 50+ human cases, underscoring both safety and simplicity.

New Data Highlight:

Dr. Mohamed Abeid’s latest peer-reviewed study (Obesity Surgery, May 2025) explores antral application of Gen 1 EndoBand™. Among 12 women treated, the antrum-targeted group lost an average of 16.2% total body weight in just 3 months, outperforming the gastric body group in efficacy, tolerability, and procedural simplicity.

Clear Difference: Why Gen 2 EndoBand™ Matters

Gen 1 proved the concept—Gen 2 powers the scale:

• Wider & deeper tissue capture enables engagement of the muscularis propria, promoting more durable anatomical reshaping
• Calibrated pressure control ensures safe, consistent ischemia and necrosis
• Engineered elastomeric bands are timed to hold tissue long enough for regeneration—without excessive pressure that could risk transection or perforation

With these enhancements, Gen 2 EndoBand™ transitions from KOL use to everyday endoscopy—safe, simple, and repeatable in ASC and outpatient settings worldwide.

Next Milestone: Type 2 Diabetes Clinical Trial

Launching this quarter in Santiago, Chile, our first band-assisted DMR (Duodenal Mucosal Resurfacing) trial targets glycemic control through mucosal regeneration. This 20-minute outpatient procedure requires no general anesthesia, offering an anatomical reset for diabetes—without drug dependence or high-risk surgery.

Why Now: GLP-1 vs Bariatric Surgery vs EndoBand

A 2025 NYU Langone study (ASMBS, June 2025) compared GLP-1 drugs to bariatric surgery across over 14,000 patients:

• Bariatric surgery: ~25.7% weight loss, -0.5 HbA1c
• GLP-1 drugs: ~5.3–7.6% weight loss, -0.2 HbA1c

EndoBand™ sits between them: an anatomical solution with surgery-like durability—but with outpatient simplicity and fractional cost. We're not burning, stapling, or medicating—we’re restoring.

Let’s Reshape What’s Possible—Together.

Best regards,

Fritz Haller

CEO | Endolastic, Inc
Endolastic.com